PLAT and Stroke: With respect to treatment, of the 24 patients (12.5%) admitted within the therapeutic window (stroke-door time of up to 4.5 h), only 5 patients (2.6%) received acute treatment with recombinant tissue plasminogen activator (rtPA) as prevention strategies.